Although JAK2 inhibitors have only been approved for the treatment of myeloproliferative disorders [78], several preclinical studies have shown the implication of the JAK/STAT pathway in solid tumours [79–81]. This evidence concerns the gene JAK2 and myeloproliferative disorder.